Opportunities and challenges for targeted radionuclide therapy of prostate cancer using 161Tb

Clement Morgat; Michiel Van de Voorde; S. Bodin; C. Champion; E. Hindié

doi:10.1016/j.mednuc.2023.09.002

Opportunities and challenges for targeted radionuclide therapy of prostate cancer using 161Tb

Clement Morgat, Michiel Van de Voorde, S. Bodin, C. Champion, E. Hindié

TRT-Radiochemistry

Research output › peer-review

Abstract

161Tb has aroused great interest to improve response rate of targeted radionuclide therapy due to its unique decay features. In this review article, decay properties of medically relevant radionuclides of the terbium element are first described. Next, modeling studies, production, preclinical and clinical studies performed using 161Tb in prostate cancer are reviewed.

Original language	French
Pages (from-to)	333-338
Number of pages	6
Journal	Médecine Nucléaire
Volume	47
Issue number	6
Early online date	5 Oct 2023
DOIs	https://doi.org/10.1016/j.mednuc.2023.09.002
State	Published - Nov 2023

ASJC Scopus subject areas

Radiological and Ultrasound Technology
Biophysics
Radiology Nuclear Medicine and imaging

Access to Document

10.1016/j.mednuc.2023.09.002

Cite this

@article{d768cb8471574d3ab4b6864b32c2382b,

title = "Opportunities and challenges for targeted radionuclide therapy of prostate cancer using 161Tb",

abstract = "161Tb has aroused great interest to improve response rate of targeted radionuclide therapy due to its unique decay features. In this review article, decay properties of medically relevant radionuclides of the terbium element are first described. Next, modeling studies, production, preclinical and clinical studies performed using 161Tb in prostate cancer are reviewed.",

keywords = "177Lu, PSMA, 161Tb, Dose, Targeted Radionuclide Therapy, Lu, Targeted radionuclide therapy, Tb",

author = "Clement Morgat and {Van de Voorde}, Michiel and S. Bodin and C. Champion and E. Hindi{\'e}",

note = "Score=10 Funding Information: This study was conducted in the framework of the University of Bordeaux IdEx “Investments for the Future” program RRI “NewMOON” that received financial support from the French Government . Publisher Copyright: {\textcopyright} 2023 Elsevier Masson SAS",

year = "2023",

month = nov,

doi = "10.1016/j.mednuc.2023.09.002",

language = "French",

volume = "47",

pages = "333--338",

journal = "M{\'e}decine Nucl{\'e}aire",

issn = "0928-1258",

publisher = "Elsevier Editions Scientifiques Medicales",

number = "6",

}

TY - JOUR

T1 - Opportunities and challenges for targeted radionuclide therapy of prostate cancer using 161Tb

AU - Morgat, Clement

AU - Van de Voorde, Michiel

AU - Bodin, S.

AU - Champion, C.

AU - Hindié, E.

N1 - Score=10 Funding Information: This study was conducted in the framework of the University of Bordeaux IdEx “Investments for the Future” program RRI “NewMOON” that received financial support from the French Government . Publisher Copyright: © 2023 Elsevier Masson SAS

PY - 2023/11

Y1 - 2023/11

N2 - 161Tb has aroused great interest to improve response rate of targeted radionuclide therapy due to its unique decay features. In this review article, decay properties of medically relevant radionuclides of the terbium element are first described. Next, modeling studies, production, preclinical and clinical studies performed using 161Tb in prostate cancer are reviewed.

AB - 161Tb has aroused great interest to improve response rate of targeted radionuclide therapy due to its unique decay features. In this review article, decay properties of medically relevant radionuclides of the terbium element are first described. Next, modeling studies, production, preclinical and clinical studies performed using 161Tb in prostate cancer are reviewed.

KW - 177Lu

KW - PSMA

KW - 161Tb

KW - Dose

KW - Targeted Radionuclide Therapy

KW - Lu

KW - Targeted radionuclide therapy

KW - Tb

UR - https://ecm.sckcen.be/OTCS/llisapi.dll/open/57761941

UR - http://www.scopus.com/inward/record.url?scp=85173349114&partnerID=8YFLogxK

U2 - 10.1016/j.mednuc.2023.09.002

DO - 10.1016/j.mednuc.2023.09.002

M3 - Literature review

SN - 0928-1258

VL - 47

SP - 333

EP - 338

JO - Médecine Nucléaire

JF - Médecine Nucléaire

IS - 6

ER -